Pfizer Says Its Drugs Will Face No Tariffs for Three Years
Pfizer announced that, after agreeing to expand manufacturing and change its pricing strategy, its imported drugs will not be tariffed.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
"We've agreed to a three-year grace period during which time Pfizer products under a Section 232 investigation won't face tariffs, provided we further invest in manufacturing in the United States," the company said.
Pfizer said it has agreed to launch new medicines at price parity with "other key developed markets," to offer direct-to-consumer discounts through TrumpRx.gov, and to implement other "measures designed to ensure Americans receive comparable drug prices to those available in other developed countries."